Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on May 12 provided a corporate update and reported financial results for the first quarter ended March 31, 2014. The company’s first quarter revenues totalled $6.8 million, including $2.9 million in net product sales of BELVIQ, of which $2.7 million represented 31.5% of Eisai’s net product sales and $0.2 million related to redemptions of the 15-day free voucher. Net loss was $25.3 million, or $0.12 per share. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) net profit margin is -24.00% and weekly performance is -6.42%. On last trading day company shares ended up $6.41. Analysts mean target price for the company is $8.06. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -1.50%.
Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, announced recent highlights and financial results for the first quarter of 2014. 1Q 2014 net loss of $16.6 million, or $0.54 per share, which included $2.6 million ($0.09 per share) of non-cash expenses. Omeros Corporation (NASDAQ:OMER) shares fell -8.67% in last trading session and ended the day on $11.06. OMER return on assets is -229.70%.Omeros Corporation (NASDAQ:OMER) quarterly performance is -9.05%.
On May 8, 2014, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued a press release announcing its financial condition and results of operations for the three months ended March 31, 2014. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares moved down -6.71% in last trading session and was closed at $3.20, while trading in range of $3.20 – $3.43. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) year to date (YTD) performance is -26.27%.
ArQule, Inc. (NASDAQ:ARQL) reported Q1 EPS of ($0.11), in-line with the analyst estimate of ($0.11). At March 31, 2014, the Company had a total of $85,758,000 in cash, equivalents and marketable securities. ArQule, Inc. (NASDAQ:ARQL) ended the last trading day at $1.42. Company weekly volatility is calculated as 7.28% and price to cash ratio as 1.19.ArQule, Inc. (NASDAQ:ARQL) showed a negative weekly performance of -5.96%.
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) started enrolling patients in a late-stage clinical trial of a treatment for major bleeding in patients taking common anticoagulants. Portola Pharmaceuticals Inc. (NASDAQ:PTLA) shares moved down -6.22% in last trading session and was closed at $22.46, while trading in range of $22.38 – $24.47. Portola Pharmaceuticals Inc. (NASDAQ:PTLA) year to date (YTD) performance is -12.78%.